PATS Lung Fibrosis Co-Culture Model for Alveolar Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanisms by which alveolar epithelial cells transition from cuboidal surfactant-producing type-2 cells to thin type-1 cells during lung regeneration and the role of these transitions in pathological states such as lung fibrosis and emphysema are not well understood, particularly in terms of cell shape changes, gene expression, and DNA repair.
Innovation Solution
A lung injury organoid model is developed using a co-culture of pre-alveolar type-1 transitional cell state (PATS) cells and alveolar fibroblasts, with agents applied to study expression markers and signaling pathways, and an ex vivo model is created by ablation of AEC1 cells to analyze biological effects, incorporating agents to modulate PDGFR and RUNX signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If transitional cell states (PATS) are identified and co-cultured with fibroblasts to create fibrosis models, then disease modeling capability and drug discovery potential are improved, but system complexity and experimental setup requirements increase
Solution Approach 1:
The patent segments the complex fibrosis modeling process into distinct modular components: PATS cell isolation protocols, fibroblast co-culture systems, and standardized assay platforms. This modular segmentation enables the complex disease modeling capability to be built from manageable, reusable modules, reducing the perceived complexity while maintaining high adaptability across different fibrosis models
Solution Approach 2:
The patent develops universal co-culture platforms and standardized protocols that can model multiple types of lung fibrosis (IPF, drug-induced, radiation-induced) using the same basic PATS-fibroblast interaction framework. This multi-functionality allows a single experimental system to address diverse fibrosis conditions, improving versatility without proportionally increasing complexity
2Loss of information
If PATS cells are isolated and co-cultured with alveolar fibroblasts to study fibrosis mechanisms, then insight into disease progression and therapeutic targets is improved, but time and resources required for model development increase
Solution Approach 1:
The patent performs preliminary characterization of PATS cell signatures, fibroblast response patterns, and key interaction pathways before full-scale fibrosis modeling. This preliminary action establishes baseline data, validated protocols, and predictive markers that accelerate subsequent model development and reduce the time needed to interpret fibrosis mechanisms
Solution Approach 2:
The patent introduces standardized intermediary assays and proxy markers that mediate between complex cellular interactions and interpretable disease mechanism insights. These intermediaries (such as quantifiable fibroblast activation markers, extracellular matrix deposition measures, and inflammatory cytokine profiles) translate complex PATS-fibroblast dynamics into measurable parameters, reducing both time and resource requirements while maintaining mechanistic understanding
Data Source
AI summary
The present disclosure provides a newly-identified transitional cell state in alveolar regeneration, models to ablate lung alveolar type-1 cells that leads to lung fibrosis and emphysema, a scalable, an ex vivo lung fibrosis model that uses co-cultured lung fibroblasts and pre-alveolar type-1 transitional cell state (PATS) for the use of disease modeling and drug screening, and methods of using same.